FORM 12b-25




SEC File Number: 001-35963


CUSIP Number: 64132K102


(Check One): x Form 10-K  ¨ Form 20-F  ¨ Form 11-K  ¨ Form 10-Q  ¨ Form 10-D
  ¨ Form N-CEN  ¨ Form N-CSR


For Period Ended: September 30, 2019  


¨Transition Report on Form 10-K


¨Transition Report on Form 20-F


¨Transition Report on Form 11-K


¨Transition Report on Form 10-Q


For the Transition Period Ended:    


Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:






NeuBase Therapeutics, Inc.

Full Name of Registrant


Ohr Pharmaceutical, Inc.

Former Name if Applicable


700 Technology Drive

Address of Principal Executive Office (Street and Number)


Pittsburgh, Pennsylvania 15219

City, State and Zip Code






RULES 12b-25(b) AND (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)


  (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;


(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.





State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.


NeuBase Therapeutics, Inc. (the “Company”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended September 30, 2019 (the “Form 10-K”), within the prescribed time period because it requires additional time to complete its financial statements; accordingly, the Company’s independent registered accounting firm, CohnReznick LLP, has not yet completed its audit of the Company’s financial statements. The Company anticipates that it will file its Form 10-K as soon as possible and within the fifteen-day grace period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended.





(1)Name and telephone number of person to contact in regard to this notification


  Sam Backenroth   (646)   450-1790  
  (Name)   (Area Code)   (Telephone Number)  


(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).                                                                         x Yes        ¨ No


(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?                                                                        ¨ Yes         x No





NeuBase Therapeutics, Inc.

(Name of Registrant as Specified in Charter)


has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.



Date:     December 31, 2019                By:  /s/ Sam Backenroth
      Sam Backenroth
      Chief Financial Officer, Treasurer and Secretary